Loading...
XNAS
VRNA
Market cap1.12bUSD
Aug 08, Last price  
105.28USD
1D
-0.11%
1Q
66.27%
Jan 2017
210,460.00%
IPO
150,300.00%
Name

Verona Pharma PLC

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
211.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
118.27%
Rev. gr., 5y
609.54%
Revenues
42m
0000000000001,841,0002,7832,351040,000,000458,000042,279,000
Net income
-173m
L+218.96%
44,73800000000000000-65,146,000-55,569,000-68,701,000-54,369,000-173,418,000
CFO
-122m
L+143.33%
000000000000000-45,076,000-33,254,000-59,862,000-50,222,000-122,203,000

Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
URL
https://www.veronapharma.com/
IPO date
Mar 30, 2005
Employees
35
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
42,279
 
458
-98.86%
Cost of revenue
47,156
17,962
76,208
Unusual Expense (Income)
NOPBT
(4,877)
(17,962)
(75,750)
NOPBT Margin
Operating Taxes
10,289
(632)
253
Tax Rate
NOPAT
(15,166)
(17,330)
(76,003)
Net income
(173,418)
218.96%
(54,369)
-20.86%
(68,701)
23.63%
Dividends
Dividend yield
Proceeds from repurchase of equity
97,496
56,909
145,890
BB yield
Debt
Debt current
2,240
1,180
675
Long-term debt
4,843
53,104
10,853
Deferred revenue
Other long-term liabilities
224,520
Net debt
(392,674)
(232,488)
(231,299)
Cash flow
Cash from operating activities
(122,203)
(50,222)
(59,862)
CAPEX
(29)
Cash from investing activities
(580)
(29)
Cash from financing activities
250,779
92,869
140,818
FCF
(26,182)
(29,698)
(75,951)
Balance
Cash
399,757
271,772
227,827
Long term investments
15,000
15,000
Excess cash
397,643
286,772
242,804
Stockholders' equity
(523,640)
(350,263)
(297,172)
Invested Capital
957,441
650,875
538,003
ROIC
ROCE
EV
Common stock shares outstanding
652,311
79,268
66,134
Price
Market cap
EV
EBITDA
(2,515)
(17,846)
(75,114)
EV/EBITDA
Interest
23,542
2,065
521
Interest/NOPBT